Bogush T A, Basharina A A, Bogush E A, Ryabinina O M, Tjulandina A S, Tjulandin S A
Blokhin Russian Cancer Research Center, Ministry of Health of the Russian Federation, Moscow, 115478, Russia.
Faculty of Fundamental Medicine, Moscow State University, Moscow, 119192, Russia.
Dokl Biochem Biophys. 2018 Sep;482(1):249-251. doi: 10.1134/S1607672918050058. Epub 2018 Nov 5.
The quantitative immunofluorescence assay of serous ovarian cancer tissue for the expression of estrogen receptors (ERα and ERβ) revealed a higher expression level of ERβ in comparison with ERα in all surgical tumor samples investigated. Significant differences in the expression level of the markers were detected "from tumor to tumor." A high expression level of both ERα (≥ 25%) and ERβ (≥ 44%) in the tumor predicts a significantly longer progression-free survival time (p < 0.01) in the patients after the first line of platinum and taxane-based adjuvant chemotherapy.
对浆液性卵巢癌组织进行雌激素受体（ERα和ERβ）表达的定量免疫荧光分析显示，在所有研究的手术肿瘤样本中，ERβ的表达水平高于ERα。在“肿瘤与肿瘤之间”检测到标志物表达水平存在显著差异。肿瘤中ERα（≥25%）和ERβ（≥44%）的高表达预示着患者在一线铂类和紫杉烷类辅助化疗后的无进展生存期显著延长（p<0.01）。
